Therefore, therapeutic reprogramming aims to modify the regulatory nodes that determine how GBM cells interpret stress, particularly points influenced by PI3K/Akt/mTOR, Ras/Raf/MEK/ERK, and PLCγ1/PKC activity, rather than merely “block autophagy” or “activate apoptosis” [14,36,111]. The gene discussed is MAP2K7; the disease is glioblastoma.